+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease



Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease



Blood 91(12): 4472-4479



We have studied the cellular and molecular responses to long-term hydroxyurea (HU) treatment in 29 severely affected young patients with sickle cell disease (mean age, 10.9 +/- 4.1 years). Patients received HU at 20 mg/kg/d on 4 consecutive days per week initially, with a monthly escalated dose avoiding marrow-toxicity (mean steady-state dose, 34.2 +/- 4.6 mg/kg/d) for 12 to 36 months (mean duration, 22 months). The studied parameters were hemoglobin F (HbF), F reticulocytes (F retics), F cells, the amount of HbF per F cell (F/F cell), polymer tendency at 40% and 70% oxygen saturation, and hemolysis. Initial HbF (Fi) was dispersed (from 0.85% to 13.9%). HbF increased in all patients but 1. HbF at maximal response (Fmax) reached a sustained level varying from a 1.5-fold to a 16-fold Fi after a variable delay (6 to 24 months). Fmax was not related to HU dosage, but triangle upF (Fmax - Fi) was strongly correlated to triangle upMCV (MCVmax - MCVi). HbF increase resulted from the increase of both F cells and F/F cell. In this rather short series, Fi and Fmax were not significantly associated with age, gender, or beta-globin haplotype. Neither Fmax nor triangle upF was related to bone marrow reserve, as measured by baseline reticulocyte or neutrophil counts. However, Fmax was highly dependent on Fi. When patients are individualized into three groups according to Fmax (group 1, Fmax >20% [12 patients]; group 2, 10% < Fmax < 20% [11 patients]; group 3, Fmax <10% [5 patients]), Fi is significantly different between groups, being the highest in group 1. In addition, the best responders (group 1) were significantly different from patients in the two other groups with higher levels of total hemoglobin, decreased bilirubin, and decreased polymer tendency.

(PDF emailed within 1 workday: $29.90)

Accession: 046087968

Download citation: RISBibTeXText

PMID: 9616141


Related references

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood 91(12): 4472-4479, June 15, 1998

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 19(4): 313-318, 1997

Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Archives of Disease in Childhood 81(5): 437-439, 1999

Long-term hydroxyurea treatment in young sickle cell patients. Current Opinion in Hematology 6(2): 115-120, 1999

Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia. European Journal of Haematology 101(6): 798-803, 2018

Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood 84(9): 3182-3188, 1994

Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine 90(6): 372-378, 2012

Responses of normal and sickle cell hemoglobin to S-nitroscysteine: Implications for therapeutic applications of NO in treatment of sickle cell disease. Biophysical Chemistry 98(1-2): 165-181, 10 July, 2002

Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin 35(1): 13-21, 2011

Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry. American Journal of Hematology 86(11): 958-961, 2011

Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience. Seminars in Oncology 19(3 Suppl 9): 67-73, 1992

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology 8(5): 669-679, 2016

Sickle cell disease: a continuing clinical and research dilemma: Bone marrow transplantation for sickle cell disease Walters, M.C. et al. (1996) New Engl. J. Med. 335, 369376 Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial Ferster, A. et al. (1996) Blood 88, 19601961. Molecular Medicine Today 2(11): 450-451, 1996

Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients. Brazilian Journal of Medical and Biological Research 36(10): 1289-1292, 2003

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 89(3): 1078-1088, 1997